London South East | The UK's favourite investor portal.

From 19 April till the 4 of may ,they waited just till the broker told them how much the spike on the RNS gave them .so they could damp the shareholders with a bucket of cold water .Just when long time suffers had enough of waiting for a bit of relief from long standing nightmare .RINSE AND REPEAT ...

mogenyx Pharma Plc Research Collaboration with Rockefeller University RNS Number : 2600N Hemogenyx Pharmaceuticals PLC 08 May 2018 Hemogenyx Pharmaceuticals Plc ("Hemogenyx" or the "Company") Research Collaboration with Rockefeller University Collaboration targeting potential new treatments for Lupus using Hemogenyx's humanized mice Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it has entered into a collaboration agreement with The Rockefeller University ("Rockefeller"), one of the world's foremost research institutions, with 82 labs dedicated to basic and translational bioscience and strong commitment to using the power of basic science to further the development of new medicines and reduce human suffering. The collaboration calls for scientists at Rockefeller to use Hemogenyx's new type of humanized mice for autoimmune disease modelling in an effort to develop new treatments for autoimmune diseases - specifically Lupus. Under the agreement, the collaborative work will be co-led by investigators at Hemogenyx and Rockefeller. Professor Alexander Tarakhovsky, a member of Hemogenyx's Scientific Advisory Board and Head of Rockefeller's Laboratory of Immune Cell Epigenetics and Signaling, will act as the principal investigator for Rockefeller. Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx, will act as the principal investigator for Hemogenyx. The Directors of Hemogenyx are confident that the collaboration does not require forms of funding that would be dilutive to Hemogenyx shareholders. Dr. Sandler commented: "This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding. Shareholders can now also see the potential for the use of our technology beyond our current bone marrow transplantation focus to treat debilitating and otherwise incurable autoimmune diseases such as Lupus." Lupus is a devastating and life-changing autoimmune disease in which the body's immune system becomes hyperactive and attacks normal, healthy tissues, resulting in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of Lupus. Lupus currently has no cure and strikes mostly women of childbearing age. Most people with Lupus develop the disease between the ages of 15-44. The first stage of the development work will create a mouse model using novel proprietary methods of mice humanization developed by Hemogenyx. By using blood stem cells from subgroups of patients with the early onset of Lupus, the pro

READ this and go a way ,go and preach somewhere else .. Hemogenyx is developing two products based on a key finding made by Dr Vladislav Sandler, the Co-Founder and Chief Executive, for the $8-9 billion bone marrow / haematopoietic stem cell transplant market which could replace chemotherapy and radiation as a means of pre-transplant conditioning, as well as addressing the problem of stem cell donor availability and issues around relapse or cell rejection after transplantation. These two products are: Conditioning product - CDX bi-specific antibodies which redirect a patient's own immune cells to eliminate unwanted blood stem cells preparing a patient for bone marrow transplantation; Cell therapy product - Cell replacement product using Human Postnatal Hemogenic Endothelial Cells (Hu-PHEC) to generate cancer-free, patient-matched blood stem cells after transplant into the patient. The products address a large and growing need and will be sold into a market that is already substantial. If successful, Hemogenyx's products will enable a much wider range of patients to be treated than is presently the case as the products should be applicable to the very many patients who are unfit for or, through the lack of suitable cell donors, unable to receive blood stem cell transplants at present. Hemogenyx has, to date, made impressive progress on the Company's two products efficiently using its limited financial resources. With the �1.6million net of expenses raised during the listing, we expect to take the initial conditioning product to readiness for clinical trials and to make significant progress with our cell therapy product. Update on Hemogenyx progress I should take this opportunity to remind shareholders of the progress made since the reverse takeover and relisting. Overall the work is progressing successfully toward our goal of submitting an Investigational New Drug ("IND") application to the US Food and Drug Administration for our CDX antibodies product. LakePharma, Inc. appointment In October last year we announced the appointment of LakePharma, Inc. as our service provider for the development and manufacturing of our CDX bi-specific antibodies lead product. LakePharma will work with us through the product development process, from discovery to biomanufacturing, as we move toward readiness for clinical trials. LakePharma, the largest US-based biologics contract research organisation, is a significant partner bringing the relevant integrated antibody engineering and bioproduction expertise we need to advance our CDX product through the necessary preclinical stages to be ready to enter the clinic within our planned timetable. University of Oxford Collaboration In November last year we confirmed a collaboration with the University of Oxford to test new means of accelerating and improving the process by which transplanted blood stem cells grow and make healthy blood cells, and which promises to has

Latest Share Chat

Member Info for gige

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)